Pulse Biosciences Reports Q1 2025 Earnings with Increased Cash Reserves and Higher Expenses
Pulse Biosciences (PLSE) reported Q1 2025 earnings with a significant increase in cash reserves, driven by warrant exercises, but also noted higher expenses and a larger net loss compared to the prior year. The company is progressing with its pilot program for the nsPFA percutaneous electrode system and has achieved clinical milestones with its 360 cardiac catheter system.
Tickers: $PLSE
Topics: cash_position clinical_milestones cost_increases financial_results net_loss